rifampin and Prostatitis

Genitourinary tuberculosis was diagnosed in 543 patients in Spanish hospital from 1978 through 2003. Of the 371 male 34 (9.2%) had orchiepididymitis. Mean age was 52.7 years and the presenting symptom was scrotal swelling and/or pain. Over 50% of cases involved the right ovotestis. Associated renal tuberculosis and active disease in extraurological organs presented in 64% and 19.2% of cases, respectively. Diagnosis was established by culture of Mycobacterium tuberculosis recovery from urine and/or purulent scrotal exudate. Genomic amplification techniques aided the diagnosis in 8 patients. Treatment was rifampin, isoniazide, and pyrazinamide or ethambutol. Eight patients required combined medical and surgical treatment.

Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Combined Modality Therapy; Comorbidity; Epididymitis; Ethambutol; Exudates and Transudates; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Mycobacterium tuberculosis; Orchitis; Prostatitis; Pyrazinamide; Retrospective Studies; Ribotyping; Rifampin; RNA, Ribosomal, 16S; Scrotum; Spain; Tuberculosis, Male Genital; Tuberculosis, Renal; Urine

Topics: Administration, Oral; Adolescent; Adult; Aged; Ampicillin; Clinical Trials as Topic; Cystitis; Female; Humans; Kidney Failure, Chronic; Male; Microbial Sensitivity Tests; Middle Aged; Prostatitis; Pyelonephritis; Rifampin; Urethritis; Urinary Tract Infections

Topics: Anti-Bacterial Agents; Brucellosis; Diagnosis, Differential; Doxycycline; Endosonography; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Organ Size; Prostate; Prostatic Neoplasms; Prostatitis; Rifampin; Treatment Outcome

Brucellosis is a major public health problem in Turkey and all over the world. Joint pain, night sweats, anorexia, weakness, loss of weight and headache are the basic symptoms of brucellosis and the illness can affect many organs. Genitourinary involvement is reported in 2-20% of cases, epididimoorchitis being the most frequent complication, however, prostatic involvement is far more uncommon. In this paper, a case of Brucella prostatitis misdiagnosed as prostate carcinoma has been presented. A 50-years-old man who was a microbiology laboratory staff has been admitted to our outpatient clinic with the complaints of joint pain, weakness, fever, urgency, difficulty and pain during urination. Since prostate specific antigen (PSA) was 23.6 ng/ml (normal value < 4 ng/ml) and free PSA (fPSA) was 3.89 ng/ml (normal value < 1 ng/ml), needle biopsy from the prostate was performed. Blood cultures performed by BACTEC 9200 (Becton Dickinson, Sparks, Md.) system yielded Brucella melitensis, and the pathological examination of the prostate biopsy revealed prostatic hyperplasia and prostatitis. Brucella standard tube agglutination titer was 1/320. Upon the diagnosis of Brucella prostatitis the patient was treated with a combination of 200 mg doxycycline and 600 mg rifampicin daily for 6 months. During the follow-up period no complication was detected in the patient and the PSA level decreased to 1.57 ng/ml and fPSA to 0.43 ng/ml. This case was reported to withdraw attention to prostatic involvement during brucellosis. Elevated PSA values with the signs and symptoms of brucellosis in endemic areas should be evaluated accordingly and appropriate therapy should be initiated without any delay.

Topics: Anti-Bacterial Agents; Bacteremia; Biopsy, Needle; Brucella melitensis; Brucellosis; Diagnosis, Differential; Doxycycline; Drug Therapy, Combination; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Rifampin

To isolate bacteria, mycoplasma and chlamydia from the urogenital tract, and to determine their antibiotic susceptibility.. Bacteria, mycoplasma and chlamydia were isolated from the urogenital tract secretion by artifical culture, and their antibiotic susceptibility was detected by disk diffusion.. The common microorganisms were S. epidermidis and corynebacberium, and the minority microorganisms were G- bacteria or E. coli. Bacteria were susceptible to amikacin, cephazolin V, rifampin, gentamycin, and docycyclin.. S. epidermidis and corynebacterium are important pathogens of the urogenital tract infection. Disk susceptibility test can be used to screen the susceptible antibiotic.

Topics: Adult; Amikacin; Cefazolin; Chlamydia; Corynebacterium; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prostatitis; Rifampin; Staphylococcal Infections; Staphylococcus epidermidis; Urethritis; Uterine Cervicitis

Prostatitis due to vancomycin-resistant enterococci has not been previously described. Reported here is a case of chronic prostatitis due to Enterococcus faecium, resistant to vancomycin, ampicillin, ciprofloxacin and doxycycline, in a 42-year-old liver transplant recipient. Treatment with a combination of rifampin and nitrofurantoin for 6 weeks resulted in long-lasting cure. Other antimicrobial agents active in vitro against vancomycin-resistant enterococci, such as quinupristin/ dalfopristin and chloramphenicol, are unlikely to achieve sufficient prostatic tissue levels to be successfully utilized for treatment of this condition.

Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Chronic Disease; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Enterococcus faecium; Gram-Positive Bacterial Infections; Humans; Liver Transplantation; Male; Nitrofurantoin; Prostatitis; Rifampin; Urine; Vancomycin

Seventy out-patients suffering from chronic bacterial prostatitis were treated with a combination of trimethoprim plus rifampicin or trimethoprim alone. A combination of 300 mg. rifampicin plus 160 mg. trimethoprim (rifaprim) was used. Forty-four patients were administered rifaprim at doses of 920 mg. (twice a day) for two months. Twenty-six patients were administered trimethoprim at doses of 320 mg. (twice a day) for two months. Cultures of the expressed prostatic secretions (EPS) yielded gram-positive bacteria in 61 patients and gram-negative bacteria in 9. In rifaprim group, clinical responses were excellent in 9 cases, moderate in 23 cases and poor in 12 cases. The efficacy rate was 73%. In trimethoprim group, excellent in 1 case, moderate in 14 cases and poor in 11 cases. The efficacy rate was 60%. Seven patients of chronic bacterial prostatitis were treated by local injection of tobramycin into the prostate. The antibiotic level in the prostatic fluid twenty-four hours after injection was very high. The pain and discomfort experienced by the patients during injection into the prostate were minimal. Local necrosis was not found after histologic or electron microscopic studies of biopsied prostatic specimen after the injection. Results show that this simple method should be valuable in the treatment of the refractory group of chronic bacterial prostatitis.

Topics: Adult; Bacterial Infections; Chronic Disease; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Humans; Injections; Male; Middle Aged; Prostate; Prostatitis; Rifampin; Tobramycin; Trimethoprim

Topics: Drug Combinations; Humans; Male; Prostatitis; Rifampin; Staphylococcal Infections; Trimethoprim

Rifampicin plus trimethoprim (rifaprim) was used to treat 20 patients with chronic prostatitis in exacerbation: 11 received 2 tablets at bedtime for 15 days followed by 1 tablet at bedtime for another 105 days, and 9 received 1 tablet in the morning and 2 tablets at bedtime for 15 days, then 2 tablets at bedtime for 15 days followed by 1 tablet at bedtime for another 90 days. All patients had an enlarged tender prostate and all but 2 were symptomatic. In 10 patients previous treatment, including co-trimoxazole in 5, had failed. Cultures of the expressed prostatic secretions yielded Staphylococcus aureus in 17 patients and gram-negative micro-organisms in 3. At the end of treatment 6 of 11 patients given the lower dosage were cured clinically and bacteriologically compared to 8 of 9 given the higher dosage. After 2 to 3 years of following 5 of 9 patients in the first group and all 7 in the second group had not suffered relapse. From our study it is evident that rifaprim is a potent drug in the treatment of chronic prostatitis caused mainly by Staphylococcus aureus. A promptness of therapeutic response and the rate of cure at the end of treatment as well as after at least 2 years of followup favor the higher drug dosage.

Topics: Adult; Chronic Disease; Drug Combinations; Humans; Male; Middle Aged; Prostatitis; Rifampin; Staphylococcal Infections; Trimethoprim

Topics: Animals; Dogs; Humans; Male; Prostatitis; Rifampin; Trimethoprim

Penetration of benemycin (rifampicin) into the prostate secretion and ejaculate of patients with chronic bacterial prostatitis was studied. It was found that oral administration of the drug in a dose of 300 mg 2 times a day provided bacteriostatic concentrations of the antibiotic in the sexual gland excretions and the treatment efficacy of patients with prostatitis.

Topics: Chronic Disease; Ejaculation; Humans; Male; Prostate; Prostatitis; Rifampin; Time Factors; Tissue Distribution

Topics: Aminosalicylic Acids; Humans; Isoniazid; Lupus Vulgaris; Male; Middle Aged; Prostatitis; Rifampin; Streptomycin; Tuberculosis, Male Genital

Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Cystitis; Female; Humans; Male; Middle Aged; Prostatitis; Pyelitis; Pyelonephritis; Rifampin; Semen; Urinary Tract Infections

Topics: Animals; Dermatomycoses; Drug Resistance, Microbial; Enterobacteriaceae Infections; Guinea Pigs; Humans; Male; Microbial Sensitivity Tests; Prostatitis; Pyoderma; Rabbits; Rats; Rifampin; Skin Diseases, Infectious; Staphylococcal Infections; Streptococcal Infections; Urethritis; Urinary Tract Infections